



**Cohere Medicare Advantage Policy –
Computed Tomography (CT), Abdomen/Pelvis**
Clinical Guidelines for Medical Necessity Review

Version: 1
Effective Date: October 29, 2024

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

© 2024 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diagnostic Imaging

Guideline Name: Cohere Medicare Advantage Policy - Computed Tomography (CT), Abdomen/Pelvis

Date of last literature review: 10/03/2024

Document last updated: 10/28/2024

Type: Adult (18+ yo) | Pediatric (0-17yo)

Table of Contents

Important Notices	2
Medical Necessity Criteria	4
Service: Computed Tomography (CT), Abdomen/Pelvis	4
Benefit Category	4
Related CMS Documents	4
Recommended Clinical Approach	4
Evaluation of Clinical Harms and Benefits	5
Medical Necessity Criteria	7
Indications	7
Non-Indications	11
Disclaimer on Radiation Exposure in Pediatric Population	11
Level of Care Criteria	12
Procedure Codes (CPT/HCPCS)	12
Medical Evidence	14
References	15
Clinical Guideline Revision History/Information	19

Medical Necessity Criteria

Service: Computed Tomography (CT), Abdomen/Pelvis

Benefit Category

Diagnostic Services in Outpatient Hospital
Diagnostic Tests (other)

Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.¹

Related CMS Documents

Please refer to the [CMS Medicare Coverage Database](#) for the most current applicable CMS National Coverage.¹⁻⁵

- [National Coverage Determination \(NCD\). Computed tomography \(CT\) \(220.1\)](#)
- [Local Coverage Determination \(LCD\). CT of the Abdomen and Pelvis \(L34415\)](#)
- [Billing and Coding: CT of the Abdomen and Pelvis \(A56421\)](#)
- [Local Coverage Determination \(LCD\). Multiple Imaging in Oncology \(L35391\)](#)
- [Billing and Coding: Multiple Imaging in Oncology \(A56848\)](#)

Recommended Clinical Approach

Computed tomography (CT) of the abdomen/pelvis should be initiated by the referring physician or an appropriate allied healthcare professional involved in the patient's care. The request should contain all the necessary information regarding the patient's signs and symptoms, history, and known and suspected diagnoses to determine the appropriate imaging modalities.⁶

Bosniak Classification¹⁻³		
Stage	Malignancy Risk (%)	Features
I	0	Hairline-thin wall; water attenuation; no septa, calcifications, or solid components; non-enhancing.
II	0	1. Few thin septa with or without perceived (not measurable) enhancement; fine calcification or a short segment of slightly thickened calcification in the wall or septa. 2. Homogeneously high-attenuating masses less than or equal to 3 cm that are sharply margined and do not enhance.
IIIF	5	1. Minimally thickened or more than a few thin septa with or without perceived (not measurable) enhancement that may have thick or nodular calcification. 2. Intrarenal non-enhancing hyperattenuating renal masses greater than 3 cm.
III	50	Thickened (less than 3 mm) wall or septa with enhancement.
IV	90	Soft tissue components (e.g., nodules) with measurable enhancement.

Evaluation of Clinical Harms and Benefits

Cohere Health uses the criteria below to ensure consistency in reviewing the conditions to be met for coverage of computed tomography (CT), abdomen/pelvis. This process helps to prevent both incorrect denials and inappropriate approvals of medically necessary services. Specifically, limiting incorrect approvals reduces the risks associated with unnecessary procedures, such as complications from surgery, infections, and prolonged recovery times.

A computed tomographic (CT) image is a display of the anatomy of a cross-section of the body developed from multiple x-ray absorption measurements made around the periphery of the body. The CT image is constructed mathematically using data arising from the section of interest that is oriented essentially perpendicular to the axial dimensions of the body. The final CT image can be accomplished in any plane.²

The potential clinical harms of using these criteria may include:

- An inherent risk of procedure: There are inherent risks of imaging, including cumulative radiation exposure, contrast, allergy, nephrotoxicity, and contrast extravasation into surrounding tissues.⁹⁻¹²
- Potential danger to pregnancy: CT imaging completed during pregnancy confers a dose of ionizing radiation to the fetus and is generally only utilized when the potential benefits of this specific imaging modality outweigh the risks to the pregnancy.¹³ Fetal risk includes fetal demise, intrauterine growth restriction, microcephaly, delayed intellectual development, risk of childhood cancer, and fetal thyroid injury.¹³
- Increased healthcare costs and complications from the inappropriate use of additional interventions.¹⁴

The clinical benefits of using these criteria include²⁰:

- Detailed images of bone, soft tissue, and blood vessels allow for diagnosing conditions as well as for treatment planning and evaluation. Exploratory surgery and biopsy may be unnecessary in some scenarios due to the detail that CT provides.^{15,31}
- Appendicitis is the most common reason for emergency abdominal surgery and is difficult to diagnose clinically. Diagnostic accuracy of acute appendicitis is 93 to 98% with CT.¹⁶ When compared to ultrasound, CT has a higher sensitivity and positive predictive value.^{17, 29}
- CT scans of thorax, abdomen, or pelvic organs have been shown to be most effective in diagnosing cancers. Due to widespread availability and relatively low cost, CT is a valuable approach for cancer screening.¹⁸
- Enhanced overall patient satisfaction and healthcare experience.

This policy includes provisions for expedited reviews and flexibility in urgent cases to mitigate risks of delayed access. Evidence-based criteria are employed to prevent inappropriate denials and ensure that patients receive medically necessary care. The criteria aim to balance the need for effective treatment with the minimization of potential harms, providing numerous

clinical benefits in helping avoid unnecessary complications from inappropriate care.

In addition, the use of these criteria is likely to decrease inappropriate denials by creating a consistent set of review criteria, thereby supporting optimal patient outcomes and efficient healthcare utilization.

Medical Necessity Criteria

Indications

→ **Computed tomography (CT), abdomen or abdomen/pelvis** is considered appropriate if **ANY** of the following is **TRUE**⁶:

◆ **ANY** of the following indications:

- Abdominal, including pain in the general abdomen, lower abdomen, or pelvic area^{2,19-21}; **OR**
- Abnormality in the hepatobiliary system (e.g., liver, bile ducts, gallbladder, and associated structures); **OR**
- Diffuse liver disease (e.g., cirrhosis, steatosis, iron deposition disease); **OR**
- Autoimmune or inflammatory processes (e.g., pancreatitis³⁰ autoimmune hepatitis, primary biliary cirrhosis); **OR**
- Preoperative or postoperative evaluation; **OR**
- Splenic or perisplenic abnormalities; **OR**
- Abnormalities of the kidneys and adrenal gland when **ANY** of the following is **TRUE**^{7-10,36-37}:
 - Characterization of renal cysts that do not appear to be simple on ultrasound⁷⁻⁸; **OR**
 - Indeterminate renal and adrenal masses; **OR**
- Abdominal masses or fluid collections, known or suspected²; **OR**
- Abnormalities in abdominal or pelvic vascular structures (e.g., aortic aneurysm, pulsatile abdominal mass, retroperitoneal bleed³⁸, etc.)²; **OR**
- Trauma²; **OR**
- Clarification of findings from other imaging studies of the abdomen²; **OR**
- Confirmation of abdominal pathology suggested by laboratory abnormalities²; **OR**
- Guidance for interventional diagnostic or therapeutic procedures²; **OR**
- Planning for radiation therapy²; **OR**

- Evaluation for transcatheter aortic valve implantation/replacement (TAVI/TAVR) if patient has not undergone a CT of the abdomen within the preceding 60 days^{2,22-24}; **OR**
- Neoplastic conditions for **ANY** of the following⁴:
 - Initial staging; **OR**
 - Treatment planning; **OR**
 - Response assessment; **OR**
 - Surveillance, and **ANY** of the following is **TRUE**^{4-5,26-28}:
 - ◆ The patient is assumed to have either no known disease or disease that is stable or clinically insignificant (every 6-12 months for an overall duration [e.g., 5 years]); **OR**
 - ◆ Suspected recurrence/progression; **OR**
 - ◆ Evaluation of response to treatment when a change in therapy is contemplated; **OR**
- Conditions related to the prostate, including **ANY** of the following²:
 - Prostatitis when symptoms are worsening despite treatment; **OR**
 - Prostate cancer for **ANY** of the following indications:
 - ◆ Initial staging
 - ◆ Assessment of treatment response when carcinoma is poorly differentiated; **OR**
 - ◆ Restaging, when metastases are suspected; **OR**
- Unexplained lymphadenopathy²; **OR**
- Genitourinary (GU) disorders including **ALL** of the following:
 - when the physician cannot make a diagnosis based on physical exam and/or ultrasound²; **AND**
 - **ANY** of the following:
 - ◆ Further evaluation of known bladder pathology seen on cystoscopy or ultrasound²; **OR**
 - ◆ Other reproductive organs, including the uterus/ovaries/testicle/fallopian tube/cervix when ultrasound is indeterminate (MRI is preferred)²; **OR**
 - ◆ An undescended testicle (MRI is preferred); **OR**
 - ◆ Postpartum hemorrhage³²; **OR**
 - ◆ Ovarian cysts or indeterminate masses; **OR**

- ◆ Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality), in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following is **TRUE**:
 - New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
 - One-time clarifying follow-up of a prior indeterminate finding; **OR**
 - In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

→ **Computed tomography (CT), abdomen/pelvis with contrast** is **NOT** considered appropriate if **ANY** of the following is **TRUE**²⁵:

- ◆ History of anaphylactic allergic reaction to iodinated contrast media.

*NOTE: The referring professional and radiologist should discuss the risks and benefits of contrast media administration, including possible prophylaxis, in patients with chronic or worsening kidney disease or severe renal failure.

**NOTE: CT in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

***NOTE: CT in patients with claustrophobia should be requested at the discretion of the ordering provider.

Disclaimer on Radiation Exposure in Pediatric Population

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

Radiation Dose Optimization: Adhere to the lowest effective dose principle for

pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.^{11,33}

Alternative Modalities: Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT, fluoroscopy, or radiography.^{11,33}

Cumulative Dose Monitoring: Implement systems to track cumulative radiation exposure in pediatric patients, particularly for those requiring multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.^{11,33}

CT Imaging Considerations: When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.^{11,33}

Cohere Imaging Gently Guideline

The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.

Level of Care Criteria

Inpatient or Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
72192	Computed tomography (CT), pelvis; without contrast material
72193	Computed tomography (CT), pelvis; with contrast material
72194	Computed tomography (CT), pelvis; without contrast material, followed by contrast material(s) and further sections
74150	Computed tomography (CT), abdomen; without contrast material
74160	Computed tomography (CT), abdomen; with contrast material
74170	Computed tomography (CT), abdomen; without contrast material, followed by contrast material(s) and further sections
74176	Computed tomography (CT), abdomen and pelvis; without contrast material
74177	Computed tomography (CT), abdomen and pelvis; with contrast material
74178	Computed tomography, abdomen and pelvis; without contrast material in one or both body regions, followed by contrast material(s) and further sections in one or both body regions
76380	Computed tomography, limited or localized follow-up study

Disclaimer: G, S, I, and N Codes are non-covered per CMS guidelines due to their experimental or investigational nature.

Medical Evidence

Shah et al. (2022) performed a retrospective review of patients who had at least one CT scan of the abdomen (\pm pelvis) or MRI of the abdomen (\pm pelvis) at least 30 days post-diagnosis of Crohn's disease (CD) or ulcerative colitis (UC). The review identified factors associated with patients undergoing more than 5 CT scans of the abdomen between 2010 and 2019 and included 176,110 patients with CD and 143,460 patients with UC. From 2010 to 2019, the prevalence of individuals undergoing at least one annual CT scan of the abdomen increased with a mean annual percentage change of +3.6% for CD and +4.9% for UC. A 3.8% increase was found in the proportion of CD patients receiving greater than or equal to 5 CT scans of the abdomen annually compared to a 2.4% increase among UC patients over the ten years. The authors conclude that the prevalence of CT scans in IBD patients has escalated. Future research is needed regarding the determinants influencing the utilization of CT and MRI scans.³⁴

Oldroyd et al. (2021) conducted a meta-analysis that focused on using CT to identify underlying asymptomatic cancers. CT scans of thorax, abdomen, or pelvic organs proved to be the most effective in diagnosing cancer cases, accounting for most detections (5 out of 18, 28%). Due to widespread availability and relatively low cost, CT scanning is a potentially valuable approach for cancer screening.¹⁸

Baron et al. (2018) performed a systematic review and meta-analysis on the accuracy of CT in the diagnosis of intra-abdominal injuries in patients presenting to the emergency department (ED) with anterior abdominal stab wounds. The study aimed to assess the precision of abdominal and pelvic computed tomography (CTAP) in diagnosing intra-abdominal injuries that necessitate therapeutic laparotomy (THER-LAP) in ED patients with acute abdominal or abdominal and pelvic blunt trauma. A total of 575 patients were included. For stable patients with suspected abdominal aortic syndromes, relying solely on a negative CT scan without a period of observation is insufficient to rule out significant intra-abdominal injuries.³⁵

References

1. Centers for Medicare and Medicaid Services (CMS). National coverage determination: Computed tomography (220.1). Effective Date March 12, 2008. Accessed October 3, 2024.
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
2. Centers for Medicare and Medicaid Services (CMS). Local coverage determination: CT of the abdomen and pelvis (L34415). Revision Effective Date August 28, 2022. Accessed September 25, 2024.
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
3. Centers for Medicare and Medicaid Services (CMS). Billing and Coding: CT of the abdomen and pelvis (A56421). Revision Effective Date October 1, 2024. Accessed October 3, 2024.
<https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56421&ver=32>
4. Centers for Medicare and Medicaid Services (CMS). Local coverage determination: Multiple imaging in oncology (L35391). Revision Effective Date November 14, 2019. Accessed September 17, 2024.
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
5. Centers for Medicare and Medicaid Services (CMS). Billing and coding: Multiple imaging in oncology (A56848). Revision Effective Date January 1, 2021. Accessed October 1, 2024.
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
6. American College of Radiology (ACR), Society for Advanced Body Imaging (SABI), Society of Abdominal Radiology (SAR), Society for Pediatric Radiology (SPR). ACR–SABI–SAR–SPR practice parameter for the performance of computed tomography (CT) of the abdomen and computed tomography (CT) of the pelvis - resolution 46. Updated 2021. Accessed August 14, 2024.
<https://www.acr.org/-/media/ACR/Files/Practice-Parameters/ct-abd-pel.pdf>.
7. Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak classification of cystic renal masses, version 2019: An updated proposal and needs assessment. *Radiology*. 2019 Aug;292(2):475-488. doi: 10.1148/radiol.2019182646. PMID: 31210616; PMCID: PMC6677285.

8. Nicolau C, Antunes N, Paño B et al. Imaging characterization of renal masses. *Medicina (Kaunas)*. 2021;57(1):51. Published 2021 Jan 8. doi: 10.3390/medicina57010051. PMID: 33435540.
9. Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. *Life Sci*. 2020;259:118379. doi: 10.1016/j.lfs.2020.118379. PMID: 32890604.
10. Rudnick MR, Leonberg-Yoo AK, Litt HI, et al. The controversy of contrast-induced nephropathy with intravenous contrast: what is the risk?. *Am J Kidney Dis*. 2020;75(1):105-113. doi: 10.1053/j.ajkd.2019.05.022. PMID: 31473019.
11. The Image Gently Alliance. Procedures - image gentle and CT scans. Updated 2014. Accessed September 30, 2024. <https://www.imagegently.org/Procedures/Computed-Tomography>.
12. Summers LN, Harry ML, Colling KP. Evaluating our progress with trauma transfer imaging: repeat CT scans, incomplete imaging, and delayed definitive care. *Emerg Radiol*. 2021;28(5):939-948. doi: 10.1007/s10140-021-01938-x. PMID: 34050410.
13. Nguyen T, Bhosale PR, Cassia L, et al. Malignancy in pregnancy: multimodality imaging and treatment. *Cancer*. 2023;129(10):1479-1491. doi: 10.1002/cncr.34688. PMID: 36907983.
14. Kjelle E, Brandsæter IØ, Andersen ER, Hofmann BM. Cost of low-value imaging worldwide: a systematic review. *Appl Health Econ Health Policy*. 2024;22(4):485-501. doi: 10.1007/s40258-024-00876-2. PMID: 38427217.
15. United States Food and Drug Administration (FDA). Computed tomography. Revised May 1, 2023. Accessed October 3, 2024. <https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/computed-tomography-ct>.
16. Bahrami M, Mirgaloyebayat H, Mohajeri Z, et al. The diagnostic value of the computed tomography scan and ultrasonography in acute appendicitis. *Am J Nucl Med Mol Imaging*. 2023 Feb 15;13(1):11-17. PMID: 36923598; PMCID: PMC10009470.
17. Zisman A, Novi B, Gaughan J, et al. Factors affecting utilization of CT scan following ultrasound evaluation of suspected appendicitis. *J Osteopath Med*. 2022 Mar 3;122(6):313-318. doi: 10.1515/jom-2021-0251. PMID: 35245969.
18. Oldroyd AGS, Allard AB, Callen JP, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic

- inflammatory myopathies. *Rheumatology (Oxford)*. 2021 Jun 18;60(6):2615–2628. doi: 10.1093/rheumatology/keab166. PMID: 33599244.
19. Haller O, Karlsson L, Nyman R. Can low-dose abdominal CT replace abdominal plain film in evaluation of acute abdominal pain?. *Ups J Med Sci*. 2010;115(2):113–120. doi:10.3109/03009730903294871. PMID: 19878040.
 20. Pandharipande PV, Reisner AT, Binder WD, et al. CT in the emergency department: a real-time study of changes in physician decision making. *Radiology*. 2016;278(3):812–821. doi: 10.1148/radiol.2015150473. PMID: 26402399.
 21. Expert panel on gastrointestinal imaging: Scheirey CD, Fowler KJ, et al. ACR appropriateness criteria acute nonlocalized abdominal pain. *J Am Coll Radiol*. 2018;15(11S):S217–S231. doi: 10.1016/j.jacr.2018.09.010. PMID: 30392591.
 22. Achenbach S, Delgado V, Hausleiter J, et al. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR). *J Cardiovasc Comput Tomogr*. 2012;6(6):366–380. doi: 10.1016/j.jcct.2012.11.002. PMID: 23217460.
 23. Hawkey MC, Lauck SB, Perpetua EM, et al. Transcatheter aortic valve replacement program development: recommendations for best practice. *Catheter Cardiovasc Interv*. 2014;84(6):859–867. doi: 10.1002/ccd.25529. PMID: 24760495.
 24. Leipsic J, Gurvitch R, Labounty TM, et al. Multidetector computed tomography in transcatheter aortic valve implantation. *JACC Cardiovasc Imaging*. 2011;4(4):416–429. doi: 10.1016/j.jcmg.2011.01.014. PMID: 21492818.
 25. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. *Radiology*. 2020;294(3):660–668. doi: 10.1148/radiol.2019192094. PMID: 33015613; PMCID: PMC7525144.
 26. Ackman JB, Chung JH, et al. ACR appropriateness criteria – imaging of mediastinal masses. *J Am Coll Radiol*. 2021;18(5S):S37–S51. doi: 10.1016/j.jacr.2021.01.007. PMID: 33958117.
 27. de Groot PM, Chung JH, et al. ACR appropriateness criteria – noninvasive clinical staging of primary lung cancer. *J Am Coll Radiol*. 2019;16(5S):S184–S195. doi: 10.1016/j.jacr.2019.02.008. PMID: 31054745.
 28. Raptis CA, Goldstein A, et al. ACR appropriateness criteria – staging and

- follow-up of esophageal cancer. *J Am Coll Radiol*. 2022;19(11S): S462–S472. doi: 10.1016/j.jacr.2022.09.008. PMID: 36436970.
29. Expert panel on gastrointestinal imaging, Garcia EM, Pietryga JA, et al. ACR appropriateness criteria – hernia. *J Am Coll Radiol*. 2022 Nov;19(11S):S329–S340. doi: 10.1016/j.jacr.2022.09.016. PMID: 36436960.
30. Expert panel on gastrointestinal imaging, Porter KK, Zaheer A, et al. ACR appropriateness criteria – acute pancreatitis. *J Am Coll Radiol*. 2019 Nov;16(11S):S316–S330. doi: 10.1016/j.jacr.2019.05.017. PMID: 31685100.
31. Expert panel on musculoskeletal imaging, Garner HW, Wessell DE, et al. ACR appropriateness criteria – soft tissue masses: 2022 update. *J Am Coll Radiol*. 2023 May;20(5S):S234–S245. doi: 10.1016/j.jacr.2023.02.009. PMID: 37236746.
32. Expert panel on GYN and OB imaging, Uyeda JW, George E, et al. ACR appropriateness criteria – postpartum hemorrhage. *J Am Coll Radiol*. 2020 Nov;17(11S):S459–S471. doi: 10.1016/j.jacr.2020.09.011. PMID: 33153557.
33. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed October 3, 2024. <https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans>.
34. Shah R, Elangovan A, Jordan DW, et al. 10-year trend of abdominal magnetic resonance imaging compared with abdominal computed tomography scans in inflammatory bowel disease. *Inflamm Bowel Dis*. 2022 Sep 1;28(9):1357–1362. doi: 10.1093/ibd/izab284. PMID: 34935946.
35. Baron BJ, Benabbas R, Kohler C, et al. Accuracy of computed tomography in diagnosis of intra-abdominal injuries in stable patients with anterior abdominal stab wounds: a systematic review and meta-analysis. *Acad Emerg Med*. 2018 Jul;25(7):744–757. doi: 10.1111/acem.13380. PMID: 29369452. Erratum in: *Rheumatology (Oxford)*. 2021 Nov 3;60(11):5483. doi: 10.1093/rheumatology/keab616. PMID: 34689208.
36. Expert panel on urological imaging, Smith AD, Nikolaidis P, et al. ACR appropriateness criteria – acute pyelonephritis: 2022 update. *J Am Coll Radiol*. 2022 Nov;19(11S):S224–S239. doi: 10.1016/j.jacr.2022.09.017. PMID: 36436954.
37. Expert panel on urological imaging, Wang ZJ, Nikolaidis P, et al. ACR appropriateness criteria – indeterminate renal mass. Updated 2020.

Accessed October 4, 2024.

<https://acsearch.acr.org/docs/69367/Narrative/>.

38. Expert panel on vascular imaging, Verma N, Steigner ML, et al. ACR appropriateness criteria – suspected retroperitoneal bleed. *J Am Coll Radiol*. 2021 Nov;18(11S):S482–S487. doi: 10.1016/j.jacr.2021.09.003. PMID: 34794602.

Clinical Guideline Revision History/Information

Original Date: October 29, 2024

Review History

Review History		